Rhythm Pharmaceuticals
D

RYTM

116.155
USD
-0.46
(-0.39%)
Market Open
Last updated: · Delayed 15 min
Volume
40,254
EPS
-3
Div Yield
-
P/E
-40
Market Cap
8,039,611,860
Related Instruments

Title: Rhythm Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Common questions about Rhythm Pharmaceuticals stock